Amixide

Quick links to important sections

Amixide

Selected form

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amixide

Quick Facts

Property Description
Active ingredient Amitriptyline and Chlordiazepoxide
Form Tablet (Oral Dosage Form)
Pharmacological class Anxiolytic-Antidepressant Combination
General purpose Management of mixed anxiety-depressive states
Origin Synthetic Compound

Amixide is a synthetic psychotherapeutic agent designated as a Fixed-Dose Combination (FDC) drug, delivered as an oral dosage form in the form of a tablet. This medication is specifically designed to manage emotional states where symptoms of anxiety and depression occur together, utilizing the complementary actions of two distinct active compounds. The FDC approach is clinically recognized for improving compliance in patients who require treatment with multiple psychotropic agents simultaneously.


What Type of Medicine is Amixide?

Amixide is classified as an anxiolytic-antidepressant combination, reflecting its dual action against two core psychological conditions. Unlike single-ingredient drugs, this FDC strategy combines two different classes of psychoactive medication to provide comprehensive support in one single formulation. The medicine is intended for oral administration. Clinical observation indicates the efficacy of combination therapy, particularly in patients experiencing both significant anxiety and depression, a common clinical challenge.


Composition: Amitriptyline and Chlordiazepoxide

The drug is composed of two primary active ingredients: Amitriptyline and Chlordiazepoxide. Amitriptyline is categorized as a tricyclic antidepressant (TCA), primarily functioning to improve mood and emotional stability. Chlordiazepoxide, conversely, is a benzodiazepine—a class of drugs often referred to as minor tranquilizers—and is included to help reduce feelings of excessive worry, tension, and agitation. Both components are recognized as distinct pharmacological entities.


General Purpose of the Dual-Action Combination

The overarching goal of Amixide is to stabilize a patient's emotional state by addressing both the depressive and anxious components simultaneously, such as when a person experiences persistent sadness alongside panic or intense agitation. The inclusion of an antidepressant and an anxiolytic in one pill is intended to produce a synergistic effect, meaning their combined benefit in managing mixed states of emotional distress is potentially greater than if the components were taken separately. This dual approach aims to restore emotional balance and quickly reduce general psychological tension.

What side effects are possible with Amixide?

Possible side effects and safety information

The safety profile for Amixide (Chlordiazepoxide and Amitriptyline Hydrochloride) is established based on the officially reported adverse reactions and regulatory constraints associated with this fixed-dose combination.

Adverse Reaction Scope

The most frequently reported adverse effects in regulatory documentation are generally those related to the central nervous system (CNS) and anticholinergic activity. These include drowsiness, dry mouth (xerostomia), constipation, blurred vision, dizziness/lightheadedness, and bloating.

Adverse reactions are organized by body system, including the Central Nervous System (CNS), Cardiovascular system (e.g., arrhythmias, orthostatic hypotension, myocardial infarction), Gastrointestinal system, and Ophthalmologic system (e.g., blurred vision, risk of angle-closure glaucoma).

Serious Regulatory Safety Statements

Official labeling emphasizes several high-level risks. The medicine carries a documented risk for abuse, misuse, addiction, physical dependence, and withdrawal reactions. Furthermore, concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.

Antidepressant components are associated with an increased risk of suicidal thoughts and behaviors (suicidality) in pediatric and young adult patients, particularly during the initial months of treatment or following dosage changes. The drug is strictly contraindicated following an acute myocardial infarction and with the concurrent use of Monoamine Oxidase Inhibitors (MAOIs).

Population-Specific Considerations

Safety notes specify precautions for certain patient groups. Older adults may be more susceptible to sedative effects, orthostatic hypotension, and hyponatremia. The use in young adults is associated with the increased suicidality risk. Caution is required in patients with impaired renal or hepatic function due to potential changes in drug clearance.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

This information describes the documented overdose profile for Amixide (a combination of Chlordiazepoxide and Amitriptyline) based strictly on governmental regulatory documents and is not a substitute for medical advice.


Overdose Presentations and Risks

Urgent Medical Attention is Required for the emergence of worsening depression and/or the emergence of suicidal ideation and behavior (suicidality), or unusual changes in behavior such as anxiety, agitation, panic attacks, and mania. All patients, especially those with depression, should not have easy access to large quantities of the drug, and prescriptions should be limited to the smallest quantity consistent with good patient management to reduce the risk of overdose.

Overdose presentations and risks affecting the Central Nervous System (CNS) and Cardiovascular systems include:

  • Serious Cardiovascular Effects: High doses of the tricyclic antidepressant component have been linked to arrhythmias, sinus tachycardia, and prolongation of conduction time. Reports of Myocardial infarction and stroke have been associated with this drug class.
  • CNS Depression: The combined use with alcohol or other CNS depressants can result in a harmful level of sedation and CNS depression.
  • Severe Reactions: Life-threatening events, including hyperpyretic crises, severe convulsions, and deaths, have occurred when a tricyclic antidepressant was taken simultaneously with a Monoamine Oxidase Inhibitor (MAOI).

Therapeutic Uses of Amixide

What Amixide Treats: Main Uses and Benefits

This medication is generally used in situations involving certain distressing symptoms of both depression and anxiety that present simultaneously. The primary therapeutic indication is for the management of patients with moderate to severe depression associated with moderate to severe anxiety. The combination generally provides support that helps ease the overall symptom burden, assisting with maintaining functional stability during symptomatic periods by addressing persistent sadness alongside excessive worry and tension.


The medication is relevant for easing symptom clusters that may become intense or disruptive, including psychological tension, persistent sadness, and motor restlessness. In addition to managing these core emotional states, Amixide is also commonly used to help with related issues like insomnia and specific types of chronic neuropathic pain. This supportive relief may contribute to improved comfort and assists with maintaining functional stability during symptomatic periods.


The overall purpose is symptomatic support:

“The primary therapeutic purpose is to offer symptomatic relief that helps patients cope more steadily with difficult episodes and supports general well-being when symptoms are more noticeable.”

Quick Fact: Relief for Mixed States

Property Description
Primary Focus Moderate to severe co-occurring anxiety and depression
Symptom Types Psychological tension, persistent sadness, motor restlessness, and sleep disturbances
Patient Benefit Supports easing overall symptom load and comfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Amixide?

Eligibility for Amixide (Amitriptyline and Chlordiazepoxide) is defined by official regulatory documents based on patient health status and age.

Absolute Contraindications

Use is prohibited for patients with a known hypersensitivity to the ingredients, those in the acute recovery phase following a heart attack, and patients taking a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. It is also contraindicated in patients with angle-closure glaucoma or a history of urinary retention.

Population Group Eligibility Status (Regulatory Basis)
Pediatric Patients (under 18) Not Established/Not Recommended. Safety and efficacy are not established in this population.
Geriatric Patients (65 and over) Use requires Caution/Close Supervision due to increased sensitivity to anticholinergic and sedative effects.
Pregnancy/Lactation Generally Not Recommended. Use is restricted to cases where the benefit justifies the risk; both components pass into breast milk.

Conditional Eligibility

Caution is required for patients with severely impaired liver function, a history of seizure disorders, or certain cardiovascular disorders. These restrictions ensure the medicine is only used where the patient's underlying health status permits it, as defined by the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Amixide (Amitriptyline and Chlordiazepoxide) around prohibited combinations, pharmacodynamic reinforcement, and altered drug exposure.


Contraindicated and High-Risk Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated. This combination presents a risk for severe outcomes, including hyperpyretic crises and convulsions, officially described as a manifestation of Serotonin Syndrome. A mandatory washout period of at least 14 days is required when switching between an MAOI and Amixide. The use of other serotonergic agents, such as certain antidepressants or the herbal product St. John's Wort, also increases the risk of this condition.


Pharmacodynamic and Exposure Interactions

Concomitant use with alcohol (Ethanol) or other Central Nervous System (CNS) depressants (e.g., opioid analgesics, barbiturates) results in additive CNS depression, potentially leading to profound sedation and respiratory depression. The Amitriptyline component may also block the antihypertensive action of drugs like Guanethidine. Substances like Cimetidine and Thyroid Hormones can increase the plasma concentrations of Amixide's components, which is a pharmacokinetic interaction requiring cautious use.


Population-Specific Considerations

The drug's effects may be increased in elderly patients and individuals with liver disease due to officially recognized slower removal (reduced clearance) from the body.

Mechanism of Action

How Amixide Works: Mechanism of Action

Modulating Key Mood and Alertness Messengers

This mechanistic domain centers on Amixide's ability to inhibit the reuptake of the neurotransmitters serotonin and norepinephrine on the surface of nerve cells. By blocking reabsorption and increasing the sustained availability of these messengers in the synaptic cleft, the mechanism promotes structural and functional adjustments within emotional signaling pathways. This supports the restoration of balanced signaling within mood-related circuits.

Enhancing the Brain's Inhibitory (GABA) System

This action involves the drug's role as a positive modulator of the GABA-A receptor, thereby enhancing the effects of the brain's main inhibitory neurotransmitter, GABA. This specific mechanism increases the chloride ion flux across nerve cell membranes (inhibitory post-synaptic potential), which leads to a dampening of excessive neuronal activity and modulation of arousal levels.

Dosage and Administration Information

Official Administration Guidelines

Amixide is an oral tablet available in two fixed-dose combinations: 5 mg Chlordiazepoxide/12.5 mg Amitriptyline and 10 mg Chlordiazepoxide/25 mg Amitriptyline. The use of this medicine is structured around a principle of gradual adjustment and flexible scheduling.


Dosing and Frequency

Administration is generally structured as daily in divided doses for adults. The usual initial regimen is three or four tablets daily of either strength. While daily division is common, guidelines permit the larger portion of the total daily dose to be taken at bedtime; a single dose at bedtime may be sufficient for certain patients.

Once a satisfactory response is achieved, the dosage is typically adjusted to the smallest amount necessary to maintain the effect, ensuring the daily intake does not typically exceed six tablets of the higher strength.


Procedural and Population-Specific Rules

  • Route: The drug is for oral administration only.
  • Food Relationship: Guidelines do not specify a required relationship with food.
  • Missed Dose: If a dose is missed, it should be taken as soon as possible, but if it is near the next scheduled dose, the missed dose is skipped; doses must not be doubled.
  • Older Adults: Lower dosages are routinely recommended for elderly or debilitated patients to limit the dose to the smallest effective amount. The safety and effectiveness of this medicine in the pediatric population have not been established.
  • Discontinuation: To conclude treatment, the medicine requires a gradual taper or reduction in dosage. Abrupt discontinuation is advised against.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amixide

Evidence for Use in Moderate to Severe Depression Associated with Anxiety

Amixide, which combines the active ingredients amitriptyline and chlordiazepoxide, was studied for its approved use in adults who have moderate to severe depression conditions where symptoms may vary in intensity along with anxiety. The research examining this specific fixed-dose combination (FDC) primarily includes observational studies, often carried out after the product was made available to the public (known as post-marketing surveillance studies). These types of studies research examined short-term changes and was observed in observational settings evaluating outcomes reflecting daily functioning or activity level. They was observed in adult patient populations, but typically lacked a direct comparison group, such as a placebo or another single medication.

In these studies, researchers monitored patient-reported outcomes describing perceived discomfort and assessed symptom intensity using standardized scales like the Hamilton Depression and Anxiety Rating Scales. Findings describe patterns observed in the studies over the short term. Research provides insight into short-term changes, but the data show patterns related to non-comparative, short-term observations.

Trial Design and Outcome Measures

The research was observed in studies that examined outcomes reflecting daily functioning or activity level. These assessments tracked changes in the severity of both depressive and anxious symptoms. Researchers relied on formal rating tools relevant in evidence describing how symptoms are measured, focusing on metrics that capture phases of heightened symptom activity. The research was observed in studies exploring short-term symptom changes, with follow-up durations were limited, often spanning only a few weeks to months.

What Remains Uncertain About the Research for Amixide

The current evidence landscape for Amixide presents several limitations. Because the research often involves small sample sizes and follow-up durations were limited, the certainty remains low in some areas. The primary limitation is the lack of extensive, large-scale, double-blind, placebo-controlled trials specifically examining the FDC, meaning comparative evidence is lacking.

Findings describe group patterns, not personal outcomes, and evidence contributes to understanding symptom patterns and what is still uncertain. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Safety and effectiveness of fixed dose combination of amitriptyline and chlordiazepoxide (Libotryp® and Libotryp-DS®) in the management of depression with co-morbid anxiety: protocol and design of a prospective, single arm, multi-centric, PMS study | International Journal of Clinical Trials
  2. A placebo-controlled multicenter trial of Limbitrol versus its components (amitriptyline and chlordiazepoxide) in the symptomatic treatment of depressive illness. | Psychopharmacology

Frequently Asked Questions (FAQ)

Common questions about Amixide (FAQ)

Q: How quickly does Amixide start working after you take it?

A: Official regulatory information indicates that the overall clinical response to Amixide is generally gradual. While the benzodiazepine component may provide some more immediate relief for tension and anxiety, the full benefit of the antidepressant component may require consistent use over several weeks.

Q: What is the difference between Amixide and Xanax?

A: Amixide is a fixed-dose combination medication containing two active ingredients: a tricyclic antidepressant (Amitriptyline) and a benzodiazepine (Chlordiazepoxide). Xanax (alprazolam) is a single-ingredient drug that belongs only to the benzodiazepine class. The combination in Amixide is intended to address both the depressive and anxious aspects of a condition.

Q: Why do doctors often prescribe Amixide for digestive issues?

A: Amixide is formally approved for managing mixed anxiety and depression. One of its active components, Amitriptyline, has anticholinergic properties that can slow down gut movement. Research exists into the use of the component Amitriptyline for conditions like Irritable Bowel Syndrome (IBS), though the combination drug is not formally approved for this purpose.

Q: Can Amixide be taken long-term?

A: Official information advises that the dosage should be reduced to the smallest effective amount once a satisfactory response is achieved. Regulatory sources note that long-term use is associated with risks such as physical dependence and withdrawal reactions, and official information indicates that long-term use should involve periodic re-evaluation.

Q: What happens if I stop taking Amixide suddenly?

A: Abruptly stopping the medication is not recommended according to official regulatory documents. Suddenly discontinuing Amixide is advised against, as it carries a risk of withdrawal symptoms, which may include physical symptoms like dizziness, nausea, and headaches, or a worsening of the original condition.

Q: Is it safe to drink coffee while taking Amixide?

A: Regulatory documents include explicit warnings about combining Amixide with substances that cause Central Nervous System (CNS) depression, such as alcohol. While no blanket warning exists for caffeine (a CNS stimulant), it is important to consider that the Amitriptyline component may affect heart rhythm.

Q: Can Amixide be taken with herbal supplements like St. John's Wort?

A: Official regulatory information indicates that combining Amixide with St. John's Wort is highly cautioned against or contraindicated. Combining these substances significantly increases the risk of Serotonin Syndrome, a potentially serious condition caused by an excess of the neurotransmitter serotonin in the brain.

Q: What research supports the use of Amixide for irritable bowel syndrome (IBS)?

A: The fixed-dose combination (FDC) Amixide is approved for treating anxiety and depression. Research has been conducted on the use of the component Amitriptyline as a therapy for conditions like IBS, but these studies relate to an unapproved use for the FDC medication, and the fixed-dose combination (FDC) medication is not formally indicated for this use.

Q: How long does Amixide stay in your system?

A: Due to the long half-life of Amitriptyline and its active metabolite, Amixide takes an extended period to be fully cleared from the body. Clearance may be slower in certain populations, such as older adults and individuals with impaired liver function.

Q: What is the risk of withdrawal symptoms when stopping Amixide?

A: Amixide carries a documented risk for developing physical dependence and withdrawal reactions. Regulatory documents state that treatment should be concluded using a gradual reduction in dosage, or taper, to minimize the documented risk of withdrawal reactions.

Q: What is the usual duration of Amixide treatment?

A: Official information does not specify a single fixed duration for Amixide treatment. Treatment is managed by reducing the dosage to the smallest amount necessary to maintain a satisfactory response, with the length depending on the patient's individual response.

Q: Are there generic versions of Amixide available?

A: Amixide is a brand-name fixed-dose combination (FDC) drug. While the FDC may not have a direct generic equivalent, both of its active ingredients, Amitriptyline and Chlordiazepoxide, are individually available as generic products.

Q: Is Amixide a strong medicine?

A: Official regulatory documents classify Amixide as a psychotherapeutic agent with a potent pharmacological profile. This is reflected in the official warnings regarding its abuse potential, risk of dependency, and severe interaction warnings (e.g., MAOIs, opioids).

Q: Does Amixide help with sleep problems?

A: The official product information notes that the Amitriptyline component has sedative properties, and the Chlordiazepoxide component is a tranquilizer. Due to this sedative effect, official guidelines permit flexibility in the timing of administration, such as taking a larger portion of the dose at bedtime.

Q: Can taking Amixide affect lab test results?

A: The active ingredients have been associated with changes that may be detected by laboratory tests, such as alterations in liver function or sodium levels. These changes are noted in official adverse event reporting.

Q: Does Amixide help with physical symptoms of stress?

A: Amixide is approved to treat mixed anxiety and depression, which includes states of general psychological tension and agitation. The benzodiazepine component (Chlordiazepoxide) is included to dampen excessive nervous system activity often associated with the physical manifestations of tension.

Q: Is Amixide the same as an anxiolytic drug?

A: Amixide is not classified solely as an anxiolytic. It is officially defined as an anxiolytic-antidepressant combination because it contains both a benzodiazepine (for anxiety relief) and a tricyclic antidepressant (for mood and emotional stability) in one formulation.

Q: Can I take Amixide if I have kidney issues?

A: Official labeling advises caution for patients with impaired hepatic (liver) function. Patients with organ impairment should discuss their specific condition with a healthcare provider, as this type of medication may require close consideration.

Q: Are there any known interactions between Amixide and birth control pills?

A: The official regulatory documents do not list a specific interaction between Amixide and oral contraceptive pills. However, because the active components of Amixide are metabolized by certain liver enzymes (CYP450), there is a theoretical potential for interaction with other drugs metabolized by the same pathway.

Q: Are there any major food interactions with Amixide?

A: The official prescribing information does not specify a required relationship with food for administration and is generally silent regarding major food interactions. Consumption of alcohol, however, is cautioned against due to the risk of additive CNS depression.

How should Amixide be stored and disposed of?

How to Store and Dispose of Amixide (Chlordiazepoxide and Amitriptyline)

Amixide tablets must be stored according to official regulatory guidelines to maintain stability and prevent unintentional exposure.

Storage Conditions

Store the medication at a controlled room temperature between 20 C and 25 C (68 F and 77 F). The product must be kept in a tight container and protected from excessive heat and moisture.

It is mandatory to keep Amixide out of the reach of children.


Disposal Instructions

Unused or expired Amixide should be disposed of through a drug take-back program if one is available in the area. Unless specifically instructed by a regulator, the tablets must not be flushed down the toilet or poured into a drain. Disposal must follow local guidelines to prevent accidental access by others.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amixide found in:

A-Z Index: